Literature DB >> 23026690

Translating vaccine policy into action: a report from the Bill & Melinda Gates Foundation Consultation on the prevention of maternal and early infant influenza in resource-limited settings.

Justin R Ortiz1, Kathleen M Neuzil, Vincent I Ahonkhai, Bruce G Gellin, David M Salisbury, Jennifer S Read, Richard A Adegbola, Jon S Abramson.   

Abstract

Immunization of pregnant women against influenza is a promising strategy to protect the mother, fetus, and young infant from influenza-related diseases. The burden of influenza during pregnancy, the vaccine immunogenicity during this period, and the robust influenza vaccine safety database underpin recommendations that all pregnant women receive the vaccine to decrease complications of influenza disease during their pregnancies. Recent data also support maternal immunization for the additional purpose of preventing disease in the infant during the first six months of life. In April 2012, the WHO Strategic Advisory Group of Experts (SAGE) on Immunization recommended revisions to the WHO position paper on influenza vaccines. For the first time, SAGE recommended pregnant women should be made the highest priority for inactivated seasonal influenza vaccination. However, the variable maternal influenza vaccination coverage in countries with pre-existing maternal influenza vaccine recommendations underscores the need to understand and to address the discrepancy between recommendations and implementation success. We present the outcome of a multi-stakeholder expert consultation on inactivated influenza vaccination in pregnancy. The creation and implementation of vaccine policies and regulations require substantial resources and capacity. As with all public health interventions, the existence of perceived and real risks of vaccination will necessitate effective and transparent risk communication. Potential risk allocation and sharing mechanisms should be addressed by governments, vaccine manufacturers, and other stakeholders. In resource-limited settings, vaccine-related issues concerning supply, formulation, regulation, evidence evaluation, distribution, cost-utility, and post-marketing safety surveillance need to be addressed. Lessons can be learned from the Maternal and Neonatal Tetanus Elimination Initiative as well as efforts to increase vaccine coverage among pregnant women during the 2009 influenza pandemic. We conclude with an analysis of data gaps and necessary activities to facilitate implementation of maternal influenza immunization programs in resource-limited settings.
Copyright © 2012. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23026690     DOI: 10.1016/j.vaccine.2012.09.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  The National Vaccine Advisory Committee: reducing patient and provider barriers to maternal immunizations: approved by the National Vaccine Advisory Committee on June 11, 2014.

Authors: 
Journal:  Public Health Rep       Date:  2015 Jan-Feb       Impact factor: 2.792

2.  Review of the status and challenges associated with increasing influenza vaccination coverage among pregnant women in China.

Authors:  Suizan Zhou; Carolyn M Greene; Ying Song; Ran Zhang; Lance E Rodewald; Luzhao Feng; Alexander J Millman
Journal:  Hum Vaccin Immunother       Date:  2019-10-07       Impact factor: 3.452

Review 3.  Maternal immunization.

Authors:  Helen Y Chu; Janet A Englund
Journal:  Clin Infect Dis       Date:  2014-05-05       Impact factor: 9.079

4.  Maternal immunization: opportunities for scientific advancement.

Authors:  Richard H Beigi; Kimberly B Fortner; Flor M Munoz; Jeff Roberts; Jennifer L Gordon; Htay Htay Han; Greg Glenn; Philip R Dormitzer; Xing Xing Gu; Jennifer S Read; Kathryn Edwards; Shital M Patel; Geeta K Swamy
Journal:  Clin Infect Dis       Date:  2014-12-15       Impact factor: 9.079

5.  Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women.

Authors:  Christine E Jones; Flor M Munoz; Hans M L Spiegel; Ulrich Heininger; Patrick L F Zuber; Kathryn M Edwards; Philipp Lambach; Pieter Neels; Katrin S Kohl; Jane Gidudu; Steven Hirschfeld; James M Oleske; Najwa Khuri-Bulos; Jorgen Bauwens; Linda O Eckert; Sonali Kochhar; Jan Bonhoeffer; Paul T Heath
Journal:  Vaccine       Date:  2016-07-29       Impact factor: 3.641

Review 6.  Influenza and pregnancy: a review of the literature from India.

Authors:  Ashwini Bhalerao-Gandhi; Pankdeep Chhabra; Saurabh Arya; James Mark Simmerman
Journal:  Infect Dis Obstet Gynecol       Date:  2015-02-24

7.  Trivalent influenza vaccination randomized control trial of pregnant women and adverse fetal outcomes.

Authors:  Eric A F Simões; Marta C Nunes; Phyllis Carosone-Link; Richard Madimabe; Justin R Ortiz; Kathleen M Neuzil; Keith P Klugman; Clare L Cutland; Shabir A Madhi
Journal:  Vaccine       Date:  2019-07-19       Impact factor: 3.641

8.  Influenza epidemiology and immunization during pregnancy: Final report of a World Health Organization working group.

Authors:  Deshayne B Fell; Eduardo Azziz-Baumgartner; Michael G Baker; Maneesh Batra; Julien Beauté; Philippe Beutels; Niranjan Bhat; Zulfiqar A Bhutta; Cheryl Cohen; Bremen De Mucio; Bradford D Gessner; Michael G Gravett; Mark A Katz; Marian Knight; Vernon J Lee; Mark Loeb; Johannes M Luteijn; Helen Marshall; Harish Nair; Kevin Pottie; Rehana A Salam; David A Savitz; Suzanne J Serruya; Becky Skidmore; Justin R Ortiz
Journal:  Vaccine       Date:  2017-09-01       Impact factor: 3.641

Review 9.  A systematic review of ethical issues in vaccine studies involving pregnant women.

Authors:  Jennifer A Beeler; Philipp Lambach; T Roice Fulton; Divya Narayanan; Justin R Ortiz; Saad B Omer
Journal:  Hum Vaccin Immunother       Date:  2016-05-31       Impact factor: 3.452

10.  Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial.

Authors:  Milagritos D Tapia; Samba O Sow; Boubou Tamboura; Ibrahima Tégueté; Marcela F Pasetti; Mamoudou Kodio; Uma Onwuchekwa; Sharon M Tennant; William C Blackwelder; Flanon Coulibaly; Awa Traoré; Adama Mamby Keita; Fadima Cheick Haidara; Fatoumata Diallo; Moussa Doumbia; Doh Sanogo; Ellen DeMatt; Nicholas H Schluterman; Andrea Buchwald; Karen L Kotloff; Wilbur H Chen; Evan W Orenstein; Lauren A V Orenstein; Julie Villanueva; Joseph Bresee; John Treanor; Myron M Levine
Journal:  Lancet Infect Dis       Date:  2016-05-31       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.